Monocyte Chemotactic Protein-1 Expression As a Prognosic Biomarker in Patients with Solid Tumor: a Meta Analysis

Overview

Journal Int J Clin Exp Pathol

Specialty Pathology

Date 2014 Aug 15

PMID 25120764

Citations 14

Authors

Hong Wang

Qiongwen Zhang

Hongyu Kong

Yunhui Zeng

Meiqin Hao

Ting Yu

Jing Peng

Zhao Xu

JingQuan Chen

Huashan Shi

Affiliations

Soon will be listed here.

Abstract

Purpose: A great deal of studies have been performed on the prognostic value of monocyte chemotactic protein-1 (MCP-1) in solid tumors in recent years. However, no consistent outcomes are reported. Therefore, the prognostic value of MCP-1 still remains controversial in patients with solid tumors. Here we aimed to evaluate the prognostic value of MCP-1 expression for patients with solid tumors.

Methods: Comprehensive literature was selected from PUBMED and EMBASE and clinical studies which reported analysis of survival data about MCP-1 in solid tumors were included. Stata 11.0 was used for performing a meta-analysis on evaluating the relation between MCP-1 and clinical staging, overall survival (OS) and disease free survival (DFS).

Results: Eleven studies with a total of 1324 patients with solid tumors were included into our meta-analysis. The result showed that high concentration of MCP-1 was related to a worse OS (HR = 1.95, 95% CI 1.32-2.88). The subgroup analysis on different location of tumors showed that high concentration of MCP-1 meant bad prognosis in patients with digestive cancer (HR = 2.66, 95% CI 1.44-4.91) and urogenital cancer (HR = 2.23, 95% CI 1.61-3.10), even head and neck cancer (HR = 1.99, 95% CI 0.95-4.18) other than respiratory cancer (HR = 1.10, 95% CI 0.39-3.11). Another subgroup analysed on different sites of cancer and indicated a poor prognosis on adenocarcinoma (HR = 2.10, 95% CI 1.63-2.69).

Conclusions: Our findings suggest that MCP-1 can be regarded as a poor prognostic maker for solid tumors and may represent important new therapeutic targets.

Citing Articles

Suppression of MCP-1, IFN-γ and IL-6 production of HNSCC by pembrolizumab added to docetaxel and cisplatin (TP) exceeding those of TP alone is linked to improved survival.

Wellhausen J, Rohl L, Berszin M, Krucken I, Zebralla V, Pirlich M Front Immunol. 2025; 15:1473897.

PMID: 39882242 PMC: 11774711. DOI: 10.3389/fimmu.2024.1473897.

Pasello G, Fabricio A, Del Bianco P, Salizzato V, Favaretto A, Piccin L J Transl Med. 2024; 22(1):242.

PMID: 38443899 PMC: 10916307. DOI: 10.1186/s12967-024-04920-6.

The Value of CXCL1, CXCL2, CXCL3, and CXCL8 as Potential Prognosis Markers in Cervical Cancer: Evidence of E6/E7 from HPV16 and 18 in Chemokines Regulation.

Fernandez-Avila L, Castro-Amaya A, Molina-Pineda A, Hernandez-Gutierrez R, Jave-Suarez L, Aguilar-Lemarroy A Biomedicines. 2023; 11(10).

PMID: 37893029 PMC: 10604789. DOI: 10.3390/biomedicines11102655.

MCP-1 expression in breast cancer and its association with distant relapse.

Mulholland B, Hofstee P, Millar E, Bliuc D, OToole S, Forwood M Cancer Med. 2023; 12(15):16221-16230.

PMID: 37341066 PMC: 10469641. DOI: 10.1002/cam4.6284.

Targeting Inflammation in Non-Small Cell Lung Cancer through Drug Repurposing.

Rajasegaran T, How C, Saud A, Ali A, Lim J Pharmaceuticals (Basel). 2023; 16(3).

PMID: 36986550 PMC: 10051080. DOI: 10.3390/ph16030451.

References

Lu X, Qian C, Mu Y, Li N, Li S, Zhang H . Serum CCL2 and serum TNF-α--two new biomarkers predict bone invasion, post-treatment distant metastasis and poor overall survival in nasopharyngeal carcinoma. Eur J Cancer. 2010; 47(3):339-46. DOI: 10.1016/j.ejca.2010.09.025. View

Fujimoto H, Sangai T, Ishii G, Ikehara A, Nagashima T, Miyazaki M . Stromal MCP-1 in mammary tumors induces tumor-associated macrophage infiltration and contributes to tumor progression. Int J Cancer. 2009; 125(6):1276-84. DOI: 10.1002/ijc.24378. View

Zhang L, Khayat A, Cheng H, Graves D . The pattern of monocyte recruitment in tumors is modulated by MCP-1 expression and influences the rate of tumor growth. Lab Invest. 1997; 76(4):579-90. View

Mestdagt M, Polette M, Buttice G, Noel A, Ueda A, Foidart J . Transactivation of MCP-1/CCL2 by beta-catenin/TCF-4 in human breast cancer cells. Int J Cancer. 2005; 118(1):35-42. PMC: 2965755. DOI: 10.1002/ijc.21291. View

Arenberg D, Keane M, DiGiovine B, Kunkel S, Strom S, Burdick M . Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000; 49(2):63-70. PMC: 11036966. DOI: 10.1007/s002620050603. View

Condeelis J, Pollard J . Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006; 124(2):263-6. DOI: 10.1016/j.cell.2006.01.007. View

Proost P, Wuyts A, Van Damme J . Human monocyte chemotactic proteins-2 and -3: structural and functional comparison with MCP-1. J Leukoc Biol. 1996; 59(1):67-74. DOI: 10.1002/jlb.59.1.67. View

Koide N, Nishio A, Sato T, Sugiyama A, Miyagawa S . Significance of macrophage chemoattractant protein-1 expression and macrophage infiltration in squamous cell carcinoma of the esophagus. Am J Gastroenterol. 2004; 99(9):1667-74. DOI: 10.1111/j.1572-0241.2004.30733.x. View

Cushing S, Berliner J, Valente A, Territo M, Navab M, Parhami F . Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc Natl Acad Sci U S A. 1990; 87(13):5134-8. PMC: 54276. DOI: 10.1073/pnas.87.13.5134. View

10.

Allavena P, Bianchi G, Zhou D, Van Damme J, Jilek P, Sozzani S . Induction of natural killer cell migration by monocyte chemotactic protein-1, -2 and -3. Eur J Immunol. 1994; 24(12):3233-6. DOI: 10.1002/eji.1830241249. View

11.

Goede V, Brogelli L, Ziche M, Augustin H . Induction of inflammatory angiogenesis by monocyte chemoattractant protein-1. Int J Cancer. 1999; 82(5):765-70. DOI: 10.1002/(sici)1097-0215(19990827)82:5<765::aid-ijc23>3.0.co;2-f. View

12.

Ohta M, Kitadai Y, Tanaka S, Yoshihara M, Yasui W, Mukaida N . Monocyte chemoattractant protein-1 expression correlates with macrophage infiltration and tumor vascularity in human esophageal squamous cell carcinomas. Int J Cancer. 2002; 102(3):220-4. DOI: 10.1002/ijc.10705. View

13.

Mantel N, Haenszel W . Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4):719-48. View

14.

Loberg R, Ying C, Craig M, Yan L, Snyder L, Pienta K . CCL2 as an important mediator of prostate cancer growth in vivo through the regulation of macrophage infiltration. Neoplasia. 2007; 9(7):556-62. PMC: 1939930. DOI: 10.1593/neo.07307. View

15.

Valkovic T, Lucin K, Krstulja M, Dobi-Babic R, Jonjic N . Expression of monocyte chemotactic protein-1 in human invasive ductal breast cancer. Pathol Res Pract. 1998; 194(5):335-40. DOI: 10.1016/S0344-0338(98)80057-5. View

16.

Salcedo R, Ponce M, Young H, Wasserman K, Ward J, Kleinman H . Human endothelial cells express CCR2 and respond to MCP-1: direct role of MCP-1 in angiogenesis and tumor progression. Blood. 2000; 96(1):34-40. View

17.

Ferlay J, Parkin D, Steliarova-Foucher E . Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010; 46(4):765-81. DOI: 10.1016/j.ejca.2009.12.014. View

18.

Qian B, Pollard J . Macrophage diversity enhances tumor progression and metastasis. Cell. 2010; 141(1):39-51. PMC: 4994190. DOI: 10.1016/j.cell.2010.03.014. View

19.

Qian Q, Sun W, Zhan P, Zhang Y, Song Y, Yu L . Role of monocyte chemoattractant protein-1, tumor necrosis factor-alpha and interleukin-6 in the control of malignant pleural effusion and survival in patients with primary lung adenocarcinoma. Int J Biol Markers. 2012; 27(2):e118-24. DOI: 10.5301/JBM.2012.9197. View

20.

Zhang X, Qin X, Qin C, Yin Y, Chen Y, Zhu H . Expression of monocyte chemoattractant protein-1 and CC chemokine receptor 2 in non-small cell lung cancer and its significance. Cancer Immunol Immunother. 2012; 62(3):563-70. PMC: 11028706. DOI: 10.1007/s00262-012-1361-y. View